New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study 1 that highlights the development and validation of a breast cancer polygenic risk score (PRS) for women of all ancestries
SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study 1 that highlights the development and validation of a breast cancer polygenic risk score (PRS) for women of all ancestries.
“PRS is one of the most powerful risk prediction tools in the field of breast cancer, and until recently a validated model had not been available to assess women of all ancestries,” said Dr. Holly Pederson, Director of Medical Breast Services at Cleveland Clinic. “Our new methodology provides a framework for a recalibrated PRS that delivers a personalized genomic breast cancer risk assessment to all women.”
The study -- first presented in an oral presentation at the 2021 ASCO Annual Meeting by Dr. Peterson – examined data from more than 275,000 women of diverse ancestral backgrounds to validate a novel method for assessing breast cancer PRS by using ancestry-informative genetic markers.
Results showed the new method of risk scoring was more accurate for women of all ancestries, indicating that weighting risk based on genetic ancestry will make it possible to deliver more reliable results to all women. Myriad has already incorporated the enhancement into the commercial offering of its MyRisk™ Hereditary Cancer Test with RiskScore®.
